Treatment of Erectile Dysfunction II
Randomized, Placebo-controlled, Double-Blind, Parallel Design, Phase 3 Study to Assess the Safety and Efficacy of Udenafil Tablets in Male Subjects With Erectile Dysfunction
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Warner Chilcott Investigational Site
-
Huntsville, Alabama, United States, 35801
- Warner Chilcott Investigational Site
-
-
Arizona
-
Tempe, Arizona, United States, 85282
- Warner Chilcott Investigational Site
-
-
California
-
Chino, California, United States, 91710
- Warner Chilcott Investigational Site
-
Tarzana, California, United States, 91356
- Warner Chilcott Investigational Site
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- Warner Chilcott Investigational Site
-
-
Connecticut
-
Milford, Connecticut, United States, 06460
- Warner Chilcott Investigational Site
-
-
Florida
-
Aventura, Florida, United States, 33180
- Warner Chilcott Investigational Site
-
Daytona Beach, Florida, United States, 32114
- Warner Chilcott Investigational Site
-
DeLand, Florida, United States, 32720
- Warner Chilcott Investigational Site
-
Ocala, Florida, United States, 34471
- Warner Chilcott Investigational Site
-
Tampa, Florida, United States, 33607
- Warner Chilcott Investigational Site
-
-
Georgia
-
Dawsonville, Georgia, United States, 30534
- Warner Chilcott Investigational Site
-
Sandy Springs, Georgia, United States, 30328
- Warner Chilcott Investigational Site
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46825
- Warner Chilcott Investigational Site
-
Greenwood, Indiana, United States, 46143
- Warner Chilcott Investigational Site
-
-
Iowa
-
West Des Moines, Iowa, United States, 50266
- Warner Chilcott Investigational Site
-
-
Maryland
-
Elkridge, Maryland, United States, 21075
- Warner Chilcott Investigational Site
-
Greenbelt, Maryland, United States, 20770
- Warner Chilcott Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89106
- Warner Chilcott Investigational Site
-
-
New Jersey
-
Lawrenceville, New Jersey, United States, 08648
- Warner Chilcott Investigational Site
-
-
New York
-
Bay Shore, New York, United States, 11706
- Warner Chilcott Investigational Site
-
Brooklyn, New York, United States, 11219
- Warner Chilcott Investigational Site
-
Kingston, New York, United States, 12401
- Warner Chilcott Investigational Site
-
New York, New York, United States, 10016
- Warner Chilcott Investigational Site
-
Poughkeepsie, New York, United States, 12601
- Warner Chilcott Investigational Site
-
Williamsville, New York, United States, 14221
- Warner Chilcott Investigational Site
-
-
North Carolina
-
Cary, North Carolina, United States, 27518
- Warner Chilcott Investigational Site
-
Raleigh, North Carolina, United States, 27612
- Warner Chilcott Investigational Site
-
Raleigh, North Carolina, United States, 27609
- Warner Chilcott Investigational Site
-
Salisbury, North Carolina, United States, 28144
- Warner Chilcott Investigational Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44122
- Warner Chilcott Investigational Site
-
-
Pennsylvania
-
Jenkintown, Pennsylvania, United States, 19046
- Warner Chilcott Investigational Site
-
Lancaster, Pennsylvania, United States, 17604-3200
- Warner Chilcott Investigational Site
-
-
South Carolina
-
Greer, South Carolina, United States, 29650
- Warner Chilcott Investigational Site
-
-
Texas
-
Arlington, Texas, United States, 76017
- Warner Chilcott Investigational Site
-
San Antonio, Texas, United States, 78229
- Warner Chilcott Investigational Site
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Warner Chilcott Investigational Site
-
Richmond, Virginia, United States, 23294
- Warner Chilcott Investigational Site
-
-
Washington
-
Mountlake Terrace, Washington, United States, 98043
- Warner Chilcott Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male, at least 19 years of age
- Stable monogamous relationship for at least 6 months with a consenting female partner who is at least 19 years of age, vaginal intercourse is a required study activity
- History of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration
- Partner is not pregnant or lactating
Exclusion Criteria:
- History of new-onset symptomatic coronary artery disease within the last 3 months or a history of myocardial infarction or cardiac surgical procedure within six months
- Cardiac arrhythmias requiring antiarrhythmic treatment
- Symptomatic congestive heart failure
- Taking nitrate medication in any form
- Uncontrolled diabetes (HbA1c ≥ 13%)
- Hypersensitivity to phosphodiesterase type 5 (PDE-5) inhibitors such as Viagra®, Cialis® or Levitra®
- Previously failed to respond to PDE-5 inhibitors such as Viagra®, Cialis® or Levitra®
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Udenafil 50 mg
50 mg Udenafil tablet plus 100 & 150 mg placebo tablets
|
Tablets via oral administration before an attempt at sexual intercourse.
Tablets via oral administration before an attempt at sexual intercourse.
|
|
Experimental: Udenafil 100 mg
100 mg Udenafil tablet plus 50 & 150 mg placebo tablets
|
Tablets via oral administration before an attempt at sexual intercourse.
Tablets via oral administration before an attempt at sexual intercourse.
|
|
Experimental: Udenafil 150mg
150 mg Udenafil tablet plus 50 & 100 mg placebo tablets
|
Tablets via oral administration before an attempt at sexual intercourse.
Tablets via oral administration before an attempt at sexual intercourse.
|
|
Placebo Comparator: Placebo
50, 100 & 150 mg placebo tablets
|
Tablets via oral administration before an attempt at sexual intercourse.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF), Baseline to Final Visit/Week 12, mITT (Modified Intent-to-Treat), LOCF (Last Observation Carried Forward)
Time Frame: Baseline and Week 12
|
Erectile Function domain: 0 - 5 scoring scale for each of 6 questions (scale: 0/min/poor - 30/max/good).
Over last month: How often were you able to get erection?
When you had erections with stimulation, how often were your erections hard enough for penetration?
When you attempted intercourse, how often were you able to penetrate your partner?
How often were you able to maintain your erection after penetrating your partner?
How difficult was it to maintain your erection to completion of intercourse?
How do you rate your confidence that you can get & keep your erection?
|
Baseline and Week 12
|
|
Changes in Sexual Encounter Profile (SEP), Question 2, Change From Baseline to Overall Study/Weeks 1-12, mITT
Time Frame: Baseline and Weeks 1-12
|
Question 2 SEP: Were you able to insert your penis into your partner's vagina?
yes/no response.
Percent yes responses at baseline compared with percent yes responses in overall study treatment period.
|
Baseline and Weeks 1-12
|
|
Changes in Sexual Encounter Profile (SEP), Question 3, Change From Baseline to Overall Study/Weeks 1-12, mITT
Time Frame: Baseline and Weeks 1-12
|
Question 3 SEP: Did your erection last long enough for you to have successful completion of intercourse?
yes/no response.
Percent yes responses at baseline compared with percent yes responses in overall study treatment period.
|
Baseline and Weeks 1-12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Satisfaction of Intercourse Domain Score Assessed by IIEF, Baseline to Week 12/Final Visit, mITT, LOCF
Time Frame: Baseline and Week 12
|
Satisfaction of Intercourse domain: 0 (poor) - 5/(good) scoring scale for each of 3 questions (0-15/good).
Over last month: How many times have you attempted sexual intercourse?
When you attempted intercourse, how often was it satisfactory for you?
How much have you enjoyed sexual intercourse?
|
Baseline and Week 12
|
|
Change in Orgasmic Function Domain Score Assessed by IIEF, Baseline to Week 12/Final Visit, mITT, LOCF
Time Frame: Baseline and Week 12
|
Orgasmic Function domain: 0/poor - 5/good scoring scale for each of 2 questions (0-10/good).
Over last month, when you had sexual stimulation or intercourse how often did you ejaculate?
When you had sexual stimulation or intercourse how often did you have the feeling of orgasm (with or without ejaculation)?
|
Baseline and Week 12
|
|
Change in Sexual Desire Domain Score Assessed by IIEF, Baseline to Week 12/Final Visit, mITT, LOCF
Time Frame: Baseline and Week 12
|
Sexual Desire domain: 1/poor - 5/good scoring scale for each of 2 questions (2-10/good).
Over last month, how often have you felt sexual desire?
How would you rate your level of sexual desire?
|
Baseline and Week 12
|
|
Change in Overall Satisfaction Domain Score Assessed by IIEF, Baseline to Week 12/Final Visit, mITT, LOCF
Time Frame: Baseline and Week 12
|
Overall Satisfaction domain: 1/poor - 5/good scoring scale for each of 2 questions (2-10/good).
Over last month, how satisfied have you been with your overall sex life?
How satisfied have you been with your sexual relationship with your partner?
|
Baseline and Week 12
|
|
Global Assessment Questionnaire (GAQ), Week 12/Final Visit, mITT Population
Time Frame: Week 12
|
While Using the Study Medication, Did You Feel That Your Erections Improved (Yes Responders)
|
Week 12
|
|
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Derived Score, Subject Version, Week 12/Final Visit, LOCF, mITT
Time Frame: Baseline and Week 12
|
EDITS -sum of responses (mapped to 0/bad-4/good scale, 11 questions standardized to scale of 100): How satisfied are you w/treatment?
How likely to continue?,
During past 4 wks, has treatment met expectations?
How easy to use ?
How satisfied w/how quickly it works?
How long it lasts?
How confident has it made you feel about ability to engage in sex?
How satisfied is partner is with treatment effects?
How does your partner feel about continuing use?
How natural did process of achieving erection feel?
Compared to before erection problem, how natural did erection feel in terms of hardness?
|
Baseline and Week 12
|
|
Change From Baseline to Week 12/Final Visit in Mean Patient Self-Assessment of Erection (PSAE), mITT Population
Time Frame: Baseline and Week 12
|
PASE: Chose one: 1) No evidence of tumescence or erection 2) partial tumescence or erection (not likely to be sufficient for penetration) 3) greater tumescence or erection sufficient for vaginal penetration, but not fully rigid 4) full rigidity; scale 1/poor, no evidence of erection - 4/good, full rigidity
|
Baseline and Week 12
|
|
Change in SEP Question 1, Change From Baseline to Overall/Weeks 1-12, mITT
Time Frame: Baseline and Weeks 1-12
|
SEP Question 1: Were you able to achieve at least some erection (some enlargement of the penis)?
yes/no response.
Percent yes responses at baseline compared with percent yes responses in overall study treatment period.
|
Baseline and Weeks 1-12
|
|
Change in SEP Question 4, Change From Baseline to Overall Study/Weeks 1-12, mITT
Time Frame: Baseline and Weeks 1-12
|
SEP Question 4: Were you satisfied with the hardness of your erection?
yes/no response.
Percent yes responses at baseline compared with percent yes responses in overall study treatment period.
|
Baseline and Weeks 1-12
|
|
Change in SEP Question 5, Change From Baseline to Overall/Weeks 1-12, mITT
Time Frame: Baseline and Weeks 1-12
|
SEP Question 5: Were you satisfied with this overall sexual experience?
yes/no response.
Percent yes responses at baseline compared with percent yes responses in overall study treatment period.
|
Baseline and Weeks 1-12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Herman Ellman, MD, Warner Chilcott
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PR-01309
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.